Symbols / MAZE Stock $26.58 +3.50% Maze Therapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
MAZE (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D.
Exch · Country NGM · United States
Market Cap 1.47B
Enterprise Value 1.00B
Income -131.12M
Sales —
FCF (ttm) -72.52M
Book/sh 7.20
Cash/sh 6.88
Employees 141
Insider 10d —
IPO Jan 31, 2025
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -7.63
PEG —
P/S —
P/B 3.69
P/C —
EV/EBITDA -7.14
EV/Sales —
Quick Ratio 15.22
Current Ratio 15.50
Debt/Eq 6.57
LT Debt/Eq —
EPS (ttm) -3.05
EPS next Y -3.48
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-06
Earnings (prior) 2026-03-25
ROA -28.01%
ROE -47.52%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 55.25M
Shs Float 29.91M
Insider Own 1.46%
Instit Own 93.83%
Short Float 9.09%
Short Ratio 2.78
Short Interest 3.80M
52W High 53.65
vs 52W High -50.46%
52W Low 8.24
vs 52W Low 222.38%
Beta —
Impl. Vol. 39.08%
Rel Volume 0.63
Avg Volume 874.22K
Volume 547.75K
Target (mean) $63.55
Tgt Median $57.00
Tgt Low $46.00
Tgt High $110.00
# Analysts 11
Recom Strong_buy
Prev Close $25.68
Price $26.58
Change 3.50%
About

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$63.55
Mean price target
2. Current target
$26.58
Latest analyst target
3. DCF / Fair value
$-23.63
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$26.58
Low
$46.00
High
$110.00
Mean
$63.55

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-14 main Truist Securities Buy → Buy $64
2026-03-31 main JP Morgan Overweight → Overweight $58
2026-03-25 reit BTIG Buy → Buy $46
2026-03-25 main HC Wainwright & Co. Buy → Buy $110
2026-03-18 init Truist Securities — → Buy $68
2026-03-16 main Wedbush Outperform → Outperform $58
2026-03-10 init Mizuho — → Outperform $97
2026-03-09 reit BTIG Buy → Buy $46
2026-03-04 main Guggenheim Buy → Buy $58
2026-01-16 main BTIG Buy → Buy $46
2025-12-04 init Wells Fargo — → Overweight $55
2025-12-03 main HC Wainwright & Co. Buy → Buy $60
2025-11-07 main Wedbush Outperform → Outperform $36
2025-09-29 main JP Morgan Overweight → Overweight $37
2025-09-18 reit HC Wainwright & Co. Buy → Buy $50
2025-09-15 main Guggenheim Buy → Buy $34
2025-09-12 main HC Wainwright & Co. Buy → Buy $50
2025-09-12 main BTIG Buy → Buy $37
2025-09-11 main BTIG Buy → Buy $37
2025-09-02 init BTIG — → Buy $30
News
RSS: Latest MAZE news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-01 BERNSTEIN HAROLD Officer — 15,000 $29.24 $441,904
2026-04-01 BERNSTEIN HAROLD Officer — 15,000 $10.42 $156,300
2026-04-01 BACHRODT AMY Officer — 2,500 $29.32 $73,611
2026-04-01 BACHRODT AMY Officer — 2,500 $10.42 $26,050
2026-03-30 DANDEKAR ATUL Officer — 7,500 $29.26 $220,019
2026-03-30 DANDEKAR ATUL Officer — 7,500 $10.42 $78,150
2026-03-20 BERNSTEIN HAROLD Officer — 15,000 $48.20 $736,439
2026-03-20 BERNSTEIN HAROLD Officer — 15,000 $10.42 $156,300
2026-03-10 BERNSTEIN HAROLD Officer — 30,000 $50.45 $1,513,560
2026-03-10 BERNSTEIN HAROLD Officer — 30,000 $10.42 $312,600
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
-100.00%
167.50
0.00
0.00
Operating Revenue
0.00
-100.00%
167.50
0.00
0.00
Operating Expense
142.90
+30.01%
109.91
+11.53%
98.55
-11.24%
111.03
Research And Development
108.45
+29.88%
83.50
+12.92%
73.94
-16.15%
88.19
Selling General And Administration
34.45
+30.41%
26.42
+7.36%
24.61
+7.76%
22.83
General And Administrative Expense
34.45
+30.41%
26.42
+7.36%
24.61
+7.76%
22.83
Other Gand A
34.45
+30.41%
26.42
+7.36%
24.61
+7.76%
22.83
Total Expenses
142.90
+30.01%
109.91
+11.53%
98.55
-11.24%
111.03
Operating Income
-142.90
-348.15%
57.59
+158.43%
-98.55
+11.24%
-111.03
Total Operating Income As Reported
-142.90
-348.15%
57.59
+158.43%
-98.55
+11.24%
-111.03
EBITDA
-140.50
-330.76%
60.88
+164.45%
-94.46
+11.89%
-107.21
Normalized EBITDA
-140.50
-330.76%
60.88
+164.45%
-94.46
+9.87%
-104.81
Reconciled Depreciation
2.40
-27.12%
3.30
-19.37%
4.09
+7.04%
3.82
EBIT
-142.90
-348.15%
57.59
+158.43%
-98.55
+11.24%
-111.03
Total Unusual Items
—
—
0.00
+100.00%
-2.40
Total Unusual Items Excluding Goodwill
—
—
0.00
+100.00%
-2.40
Special Income Charges
—
—
0.00
+100.00%
-2.40
Other Special Charges
—
—
3.83
—
Write Off
—
—
0.00
-100.00%
2.40
Net Income
-131.12
-351.04%
52.23
+152.02%
-100.42
+12.64%
-114.94
Pretax Income
-131.12
-345.53%
53.40
+153.18%
-100.42
+12.64%
-114.94
Net Non Operating Interest Income Expense
11.78
+153.09%
4.65
+136.72%
1.97
-3.06%
2.03
Net Interest Income
11.78
+153.09%
4.65
+136.72%
1.97
-3.06%
2.03
Interest Income Non Operating
11.78
+153.09%
4.65
+136.72%
1.97
-3.06%
2.03
Interest Income
11.78
+153.09%
4.65
+136.72%
1.97
-3.06%
2.03
Other Income Expense
—
-8.84
-130.73%
-3.83
+35.54%
-5.94
Other Non Operating Income Expenses
—
-8.84
-130.73%
-3.83
—
Tax Provision
0.00
-100.00%
1.17
0.00
—
Tax Rate For Calcs
0.00
-100.00%
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-131.12
-351.04%
52.23
+152.02%
-100.42
+12.64%
-114.94
Net Income From Continuing Operation Net Minority Interest
-131.12
-351.04%
52.23
+152.02%
-100.42
+12.64%
-114.94
Net Income From Continuing And Discontinued Operation
-131.12
-351.04%
52.23
+152.02%
-100.42
+12.64%
-114.94
Net Income Continuous Operations
-131.12
-351.04%
52.23
+152.02%
-100.42
+12.64%
-114.94
Normalized Income
-131.12
-351.04%
52.23
+152.02%
-100.42
+10.77%
-112.54
Net Income Common Stockholders
-131.12
-3950.81%
3.40
+103.39%
-100.42
+12.64%
-114.94
Otherunder Preferred Stock Dividend
0.00
-100.00%
33.85
0.00
—
Diluted EPS
—
0.08
+102.71%
-2.87
+12.64%
-3.29
Basic EPS
—
0.08
+102.71%
-2.87
+12.64%
-3.29
Basic Average Shares
—
43.78
+25.18%
34.97
+0.00%
34.97
Diluted Average Shares
—
43.78
+23.66%
35.40
+0.00%
35.40
Diluted NI Availto Com Stockholders
-131.12
-3950.81%
3.40
+103.39%
-100.42
+12.64%
-114.94
Earnings From Equity Interest
—
—
0.00
+100.00%
-3.54
Preferred Stock Dividends
—
14.97
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
397.13
+65.10%
240.54
+236.40%
71.50
-52.32%
149.96
Current Assets
349.72
+73.41%
201.67
+491.24%
34.11
-67.87%
106.15
Cash Cash Equivalents And Short Term Investments
341.92
+73.73%
196.81
+574.98%
29.16
-70.82%
99.92
Cash And Cash Equivalents
189.25
-3.84%
196.81
+574.98%
29.16
-70.82%
99.92
Other Short Term Investments
152.67
0.00
—
—
Other Current Assets
7.80
+60.53%
4.86
-1.88%
4.95
-20.51%
6.23
Total Non Current Assets
47.41
+21.97%
38.87
+3.95%
37.39
-14.64%
43.81
Net PPE
25.16
-15.90%
29.92
-14.48%
34.98
-15.15%
41.23
Gross PPE
44.37
-5.16%
46.78
-4.07%
48.77
-4.23%
50.93
Accumulated Depreciation
-19.21
-13.90%
-16.87
-22.35%
-13.79
-42.15%
-9.70
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
2.76
+3.18%
2.68
+1.36%
2.64
+5.98%
2.49
Construction In Progress
0.04
+37.93%
0.03
-49.12%
0.06
0.00
Other Properties
36.06
-6.64%
38.63
-5.12%
40.71
-5.55%
43.10
Leases
5.50
+0.97%
5.45
+1.72%
5.36
+0.54%
5.33
Investments And Advances
18.11
0.00
—
—
Other Non Current Assets
4.14
-53.80%
8.95
+271.49%
2.41
-6.59%
2.58
Total Liabilities Net Minority Interest
42.16
-92.36%
551.73
+23.89%
445.35
+2.99%
432.42
Current Liabilities
22.56
+9.11%
20.67
+26.70%
16.32
-21.49%
20.78
Payables And Accrued Expenses
6.91
-13.19%
7.96
+60.93%
4.95
-45.51%
9.07
Payables
1.79
-7.48%
1.94
-3.96%
2.02
+27.38%
1.58
Accounts Payable
1.79
-7.48%
1.94
-3.96%
2.02
+27.38%
1.58
Current Accrued Expenses
5.11
-15.04%
6.02
+105.71%
2.93
-60.93%
7.49
Pensionand Other Post Retirement Benefit Plans Current
10.85
+34.27%
8.08
+17.45%
6.88
-6.80%
7.38
Current Debt And Capital Lease Obligation
4.79
+3.52%
4.63
+3.19%
4.49
+3.82%
4.32
Current Capital Lease Obligation
4.79
+3.52%
4.63
+3.19%
4.49
+3.82%
4.32
Total Non Current Liabilities Net Minority Interest
19.61
-96.31%
531.05
+23.78%
429.04
+4.23%
411.63
Long Term Debt And Capital Lease Obligation
18.51
-15.84%
22.00
-51.27%
45.13
+62.76%
27.73
Long Term Debt
—
—
20.08
—
Long Term Capital Lease Obligation
18.51
-15.84%
22.00
-12.21%
25.05
-9.65%
27.73
Other Non Current Liabilities
1.09
+12.90%
0.97
—
—
Preferred Securities Outside Stock Equity
0.00
-100.00%
508.09
+32.35%
383.90
+0.00%
383.90
Stockholders Equity
354.97
+214.07%
-311.18
+16.76%
-373.85
-32.35%
-282.46
Common Stock Equity
354.97
+214.07%
-311.18
+16.76%
-373.85
-32.35%
-282.46
Capital Stock
0.05
+2350.00%
0.00
+0.00%
0.00
+0.00%
0.00
Common Stock
0.05
+2350.00%
0.00
+0.00%
0.00
+0.00%
0.00
Preferred Stock
0.00
0.00
—
—
Share Issued
49.34
+12.70%
43.78
+0.00%
43.78
+0.00%
43.78
Ordinary Shares Number
49.34
+12.70%
43.78
+0.00%
43.78
+0.00%
43.78
Additional Paid In Capital
844.35
+1687.30%
47.24
+116.35%
21.84
+70.46%
12.81
Retained Earnings
-489.55
-36.58%
-358.43
+9.42%
-395.69
-34.01%
-295.27
Gains Losses Not Affecting Retained Earnings
0.11
0.00
—
—
Other Equity Adjustments
0.11
—
—
—
Total Equity Gross Minority Interest
354.97
+214.07%
-311.18
+16.76%
-373.85
-32.35%
-282.46
Total Capitalization
354.97
+214.07%
-311.18
+12.04%
-353.77
-25.25%
-282.46
Working Capital
327.16
+80.75%
181.00
+917.19%
17.79
-79.16%
85.37
Invested Capital
354.97
+214.07%
-311.18
+12.04%
-353.77
-25.25%
-282.46
Total Debt
23.31
-12.48%
26.63
-46.34%
49.62
+54.81%
32.05
Capital Lease Obligations
23.31
-12.48%
26.63
-9.87%
29.54
-7.84%
32.05
Net Tangible Assets
354.97
+214.07%
-311.18
+16.76%
-373.85
-32.35%
-282.46
Tangible Book Value
354.97
+214.07%
-311.18
+16.76%
-373.85
-32.35%
-282.46
Available For Sale Securities
18.11
—
—
—
Investmentin Financial Assets
18.11
0.00
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-111.94
-247.38%
75.95
+187.48%
-86.83
+12.48%
-99.20
Cash Flow From Continuing Operating Activities
-111.94
-247.38%
75.95
+187.48%
-86.83
+12.48%
-99.20
Net Income From Continuing Operations
-131.12
-351.04%
52.23
+152.02%
-100.42
+12.64%
-114.94
Depreciation Amortization Depletion
2.40
-27.12%
3.30
-19.37%
4.09
+7.04%
3.82
Depreciation
2.40
-27.12%
3.30
-19.37%
4.09
+7.04%
3.82
Depreciation And Amortization
2.40
-27.12%
3.30
-19.37%
4.09
+7.04%
3.82
Other Non Cash Items
2.65
-23.54%
3.47
+7.04%
3.24
+30.83%
2.48
Stock Based Compensation
16.40
+70.02%
9.65
+10.28%
8.75
+29.85%
6.74
Asset Impairment Charge
—
—
0.00
-100.00%
2.40
Operating Gains Losses
—
—
3.83
+8.13%
3.54
Unrealized Gain Loss On Investment Securities
0.00
-100.00%
8.84
+130.73%
3.83
0.00
Change In Working Capital
-2.27
-49.24%
-1.52
+75.89%
-6.32
-95.18%
-3.24
Change In Prepaid Assets
-2.94
-3262.37%
0.09
-89.94%
0.92
+203.36%
-0.89
Change In Payables And Accrued Expense
3.46
-4.11%
3.60
+176.77%
-4.69
-546.10%
1.05
Change In Accrued Expense
3.48
-8.54%
3.81
+174.76%
-5.09
-205.45%
4.83
Change In Payable
-0.03
+86.76%
-0.20
-151.13%
0.40
+110.56%
-3.78
Change In Account Payable
-0.03
+86.76%
-0.20
-151.13%
0.40
+110.56%
-3.78
Change In Other Current Assets
0.54
+123.31%
-2.30
-6482.86%
-0.04
+95.73%
-0.82
Change In Other Current Liabilities
-3.32
-14.03%
-2.92
-16.04%
-2.51
+2.41%
-2.57
Investing Cash Flow
-170.96
-14805.14%
-1.15
-160.09%
-0.44
+86.09%
-3.17
Cash Flow From Continuing Investing Activities
-170.96
-14805.14%
-1.15
-160.09%
-0.44
+86.09%
-3.17
Net PPE Purchase And Sale
-0.79
+30.78%
-1.15
-160.09%
-0.44
+77.57%
-1.97
Purchase Of PPE
-0.79
+30.78%
-1.15
-160.09%
-0.44
+77.57%
-1.97
Capital Expenditure
-0.79
+30.78%
-1.15
-160.09%
-0.44
+77.57%
-1.97
Net Investment Purchase And Sale
-170.17
0.00
—
—
Purchase Of Investment
-187.67
0.00
—
—
Sale Of Investment
17.50
0.00
—
—
Net Business Purchase And Sale
—
—
0.00
+100.00%
-1.20
Purchase Of Business
—
—
0.00
+100.00%
-1.20
Financing Cash Flow
275.34
+196.55%
92.85
+466.66%
16.39
+848.21%
1.73
Cash Flow From Continuing Financing Activities
275.34
+196.55%
92.85
+466.66%
16.39
+848.21%
1.73
Net Issuance Payments Of Debt
0.00
-100.00%
24.48
+51.30%
16.18
0.00
Issuance Of Debt
0.00
-100.00%
24.48
+51.30%
16.18
0.00
Long Term Debt Issuance
0.00
-100.00%
24.48
+51.30%
16.18
0.00
Net Long Term Debt Issuance
0.00
-100.00%
24.48
+51.30%
16.18
0.00
Net Common Stock Issuance
270.27
0.00
—
—
Proceeds From Stock Option Exercised
5.56
+658.80%
0.73
+250.72%
0.21
+35.71%
0.15
Net Other Financing Charges
-0.50
+84.15%
-3.15
—
—
Changes In Cash
-7.57
-104.51%
167.65
+336.52%
-70.88
+29.57%
-100.64
Beginning Cash Position
197.90
+554.30%
30.25
-70.09%
101.13
-49.88%
201.77
End Cash Position
190.34
-3.82%
197.90
+554.30%
30.25
-70.09%
101.13
Free Cash Flow
-112.73
-250.70%
74.81
+185.72%
-87.27
+13.74%
-101.17
Income Tax Paid Supplemental Data
0.00
-100.00%
1.23
0.00
—
Common Stock Issuance
270.27
0.00
—
—
Earnings Losses From Equity Investments
—
—
0.00
-100.00%
3.54
Issuance Of Capital Stock
270.27
+281.78%
70.79
0.00
-100.00%
1.57
Net Preferred Stock Issuance
0.00
-100.00%
70.79
0.00
-100.00%
1.57
Preferred Stock Issuance
0.00
-100.00%
70.79
0.00
-100.00%
1.57
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category